Global Acute Ischemic Stroke Diagnosis and Treatment Market Size Study, by Type, by End User, and Regional Forecasts 2022-2032

Global Acute Ischemic Stroke Diagnosis and Treatment Market is valued at approximately USD 5.41 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 6.1% over the forecast period 2024-2032. Acute ischemic stroke is a medical condition characterized by a sudden disruption of blood flow to a part of the brain, leading to a lack of oxygen and nutrients. This ischemic event results from the blockage or obstruction of a blood vessel supplying the brain, commonly due to a blood clot or the formation of a thrombus. The sudden reduction or cessation of blood flow deprives brain cells of essential nutrients, leading to damage or death of the affected brain tissue. There are various diagnostic tests such as CT scans, MRI, and blood tests, to determine the type and severity of stroke. Ischemic stroke treatment includes the administration of anticoagulants, tissue plasminogen activators, antihypertensive medications, and antiplatelet drugs.

The growth of the acute ischemic stroke diagnosis and treatment market is driven by a rise in incidences of acute ischemic stroke around the globe and technological advancements in ischemic stroke diagnostics. For instance, according to the World Stroke Organization (WSO) 2022, each year over 58% of ischemic strokes occur in people under 70 years of age. The rise in incidence of ischemic stroke has led to an increase in demand for acute ischemic stroke diagnostics and therapeutics, which, in turn, drives the market growth. The increase in the incidence of acute ischemic stroke is a significant driver for the acute ischemic stroke diagnosis and treatment industry. Factors such as the aging population, lifestyle changes, and the increasing prevalence of risk factors like hypertension contribute to a higher occurrence of strokes, which leads to a rise in demand for diagnosis and treatment.

In addition, the rise in technological advancements in diagnostic imaging, such as computed tomography (CT) and magnetic resonance imaging (MRI), enables accurate and timely diagnosis of acute ischemic strokes, driving the acute ischemic stroke diagnosis market growth. High-resolution imaging allows healthcare professionals to visualize brain structures and identify the location and extent of ischemic damage. The aging population is more prone to stroke, and as the global population ages, the demand for stroke treatment is likely to increase. Age is a significant risk factor for stroke, and the elderly population often requires more extensive medical interventions. Thus, the rise in the geriatric population further drives the acute ischemic stroke treatment market size. Furthermore, the rise in government initiatives and support for stroke prevention and management contributes to the growth of the acute ischemic stroke diagnosis market. Funding, research programs, and the establishment of stroke centers enhance the infrastructure and capabilities for effective diagnosis and treatment, propelling the acute ischemic stroke treatment market size.

Moreover, the rise in public awareness of stroke symptoms, risk factors, and the importance of seeking immediate medical attention has led to a shift in patient behavior which supports market growth. Increased awareness contributes to early detection, diagnosis, and prompt initiation of treatment, enhancing overall outcomes which fuels the acute ischemic stroke diagnosis and treatment market growth. However, the high cost of diagnostics and treatment for ischemic stroke is projected to deter individuals from seeking early diagnosis, particularly in regions with limited access to affordable healthcare. This negatively impacts market growth. Patients may postpone or avoid diagnostic tests due to concerns about the financial burden and restrain market growth. On the other hand, technological advancement in ischemic stroke diagnosis and increase in new product approvals are expected to create lucrative acute ischemic stroke diagnosis and treatment market opportunities during the forecast period.

The ongoing global economic recession influences several industries, including medical technology and pharmaceuticals, which has an impact on the development and demand for acute ischemic stroke diagnosis and treatments. During a recession, the medical technology industry is moderately impacted due to an increase in the cost for supplies, healthcare providers, and instruments. Further, the reduction in research funding is slowing down the development of new treatment and technologies. Despite these challenges, the acute ischemic stroke diagnosis and treatment market continues to experience moderate revenue growth owing to technological advancements in imaging. Thus, the acute ischemic stroke diagnosis and treatment market is moderately impacted by the recession.

The key regions considered for the global Acute Ischemic Stroke Diagnosis and Treatment Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue in 2022. The growth in this region is attributed to the advanced healthcare infrastructure, rise in incidence of acute ischemic stroke, and adoption of technologically advanced diagnostics. In addition, the presence of several major players, such as AstraZeneca, F. Hoffmann-La Roche Ltd, Koninklijke Philips N.V., Siemens, Medtronic plc, and Abbott Laboratories contributes to the market growth in the region. Whereas, Asia-Pacific is expected to grow at the highest rate during the forecast period. This is attributed to a surge in awareness about ischemic stroke in the general population. In addition, the rise in research and clinical trials, surge in awareness, and increase in demand for advanced treatment options for acute ischemic stroke are the factors that drive the market growth in this region. Asia-Pacific offers profitable opportunities for key players operating in the acute ischemic stroke diagnosis and treatment market, thereby registering the fastest growth rate during the acute ischemic stroke diagnosis and treatment market forecast period, owing to the developments in infrastructure of industries and rise in adoption of advanced medical technologies. In addition, the rise in awareness about the benefits of timely medical intervention and the importance of early diagnosis and treatment have driven the demand for acute ischemic stroke diagnosis and treatment and propel the market growth.

Major Market Players Included in This Report Are:

• AstraZeneca
• F. Hoffmann-La Roche Ltd
• Koninklijke Philips N.V.
• Siemens
• Medtronic plc
• Abbott Laboratories
• Johnson & Johnson
• GE Healthcare
• Stryker Corporation
• Merck & Co., Inc.
• Bayer AG
• Boehringer Ingelheim
• Pfizer Inc.
• Boston Scientific Corporation
• Sanofi S.A.

The Detailed Segments and Sub-segment of the Market Are Explained Below:

By Type:

• Diagnostics
• Treatment

By End User:

• Hospitals and Clinics
• Ambulatory Surgery Centers
• Diagnostic Laboratories and Imaging Centers
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.